Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $26.07M (cash outflow) rose 25.6% year over year, behind the +31.7% change in trailing-twelve-month net income. Sequentially, it rose 49.7% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Net income amounted to 4078.8% of revenue in FY2025.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$66.08M (+4.8%) for the fiscal year ending Dec 2026, a slowdown from the +51.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.07M+49.7% QoQ
- Last fiscal yearDec 2025
- -$63.06M+51.9% YoY
- LTMMar 2026
- -$68.36M+31.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +25.6% | +111.9% | +86.4 pp |
| 1 year | +51.9% | +4.8% | -47.1 pp |
| 3-year CAGR | +2.6% | -26.5% | -29.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (63.06M) USD
- Year-over-year change
- -51.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (63.06M) | -51.9% |
| FY2024 | 2024-12-31 | (41.52M) | +30.4% |
| FY2023 | 2023-12-31 | (59.69M) | -2.2% |
| FY2022 | 2022-12-31 | (58.39M) | -36.3% |
| FY2021 | 2021-12-31 | (42.85M) | — |
Net Income vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.7% is the 2nd highest of 8, against a peer median of -8.4%.
- Net income amounts to 3832.0% of revenue for MIST, versus a peer median of 1764.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $68.36M USD | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| LTM Mar 2026 | $31.7M USD | -25.4% | -22.3% | 1000.2% | |
| Peer median (excluding MIST) | — | -8.4% | +7.4% | 1764.5% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Depreciation & Amortization | 362K | 89K | 92K | 105K | 114K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.28M | 9.05M | 9.53M | 5.78M | 7.46M |
| Change in Working Capital | 1.62M | (3.26M) | 1.24M | 3.66M | 2.68M |
| Accounts Receivables | 96K | (730K) | (2.64M) | 1.46M | (1.12M) |
| Inventory | 0 | 0 | 0 | 0 | (648K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 4.43M |
| Other Working Capital | 1.52M | (2.53M) | 3.88M | 2.2M | 17K |
| Other Non-Cash Items | 368K | 44K | 2.39M | 3.13M | 3.76M |
| Operating Cash Flow | (33.22M) | (52.47M) | (46.42M) | (28.85M) | (49.04M) |
| Capital Expenditures | 0 | (272K) | (112K) | (33K) | (302K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (15M) | (85.85M) | (137.13M) | (113.55M) | (82.92M) |
| Sales of Investments | 85M | 29M | 142M | 121.87M | 94.47M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 70M | (57.12M) | 4.76M | 8.28M | 11.25M |
| Debt Repayment | 0 | 0 | 50M | 0 | 0 |
| Common Stock Issued | 0 | 2.63M | 0 | 27.26M | 85.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.06M | 458K | (2.21M) | 4.86M | 0 |
| Financing Cash Flow | 5.06M | 3.09M | 47.79M | 32.12M | 85.53M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.83M | (106.51M) | 6.12M | 11.55M | 47.73M |
| Free Cash Flow | (33.22M) | (52.74M) | (46.54M) | (28.88M) | (49.34M) |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.